BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study Transcript
Source: SeekingAlpha
2025-10-29 12:06:35 ET
BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study October 29, 2025 8:00 AM EDT...
Read the full article on Seeking Alpha
For further details see:
BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study Transcript
BridgeBio Pharma Inc.
NASDAQ: BBIO
BBIO Trading
-0.86% G/L:
$68.375 Last:
674,082 Volume:
$68.81 Open:
BBIO Latest News
BBIO Stock Data
$13,905,867,946
157,635,809
2.34%
155
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
